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ABSTRACT
Purpose: Ewing Sarcoma Family of Tumors (ESFT), the second most common
pediatric osseous malignancy, are characterized by the pathognomonic chromosomal
EWS-ETS translocation. Outside of tumor biopsy, no clinically relevant ESFT
biomarkers exist. Additionally, tumor burden assessment at diagnosis, monitoring
of disease responsiveness to therapy, and detection of disease recurrence are limited
to radiographic imaging. To identify new, clinically relevant biomarkers we evaluated
the proteome of a subset of ESFT-derived small extracellular vesicles (sEVs).
Materials and Methods: We performed the first high quality proteomic study of
ESFT-derived sEVs from 5 ESFT cell lines representing the most common EWS-ETS fusion
types and identified 619 proteins composing the core ESFT sEV proteome. We compared
these core proteins to databases of common plasma-based proteins and sEV-associated
proteins found within healthy plasma to identify proteins unique or enriched within ESFT.
Results: From these analyses, two membrane bound proteins with biomarker
potential were selected, CD99/MIC2 and NGFR, to develop a liquid-based assay
enriching of ESFT-associated sEVs and detection of sEV mRNA cargo (i.e., EWS-ETS
transcripts). We employed this immuno-enrichment approach to diagnosis of ESFT
utilizing plasma (250 µl) from both localized and metastatic ESFT pediatric patients
and cancer-free controls, and showed significant diagnostic power [AUC = 0.92,
p = 0.001 for sEV numeration, with a PPV = 1.00, 95% CI = (0.63, 1.00) and a
NPV = 0.67, 95% CI = (0.30, 0.93)].
Conclusions: In this study, we demonstrate utilization of circulating ESFTassociated sEVs in pediatric patients as a source of minimally invasive diagnostic
and potentially prognostic biomarkers.
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INTRODUCTION

The clinical presentation of ESFT are often nonspecific in nature, with pain, swelling and discomfort
consisting of the most typical complaints and are all related
to growth of these tumors. According to the literature,
there typically is a lapse of three to nine month range
from onset of symptoms prior to time of initial diagnosis,
thus delaying initiation of oncological management [5].
Currently, diagnostic and monitoring modalities for
children and young adults with ESFT require utilization
of radiographic imaging and the important diagnostic
testing via biopsies of suspicious lesions for establishment
of diagnosis and prognosis in these patients. Although the
standard of care, these tests are expensive, invasive and
associated with potential long-term risks. Traditionally,
ESFT was considered a diagnosis of exclusion, but over
the past few decades, with the introduction of immunohistochemical markers, e.g., CD99/MIC2 and detection
of the oncogenic chimeric fusion involving the Ewing
sarcoma RNA (ribonucleic acid) binding protein 1 gene
(EWSR1 gene; Ewing sarcoma breakpoint region 1) [13],
which is a hallmark of ESFT, the accuracy of diagnosis
has considerably improved. However, these approaches
require invasive open or core biopsy sampling of active
tumor tissue [14]. The most utilized immunohistologic
stain in ESFT diagnosis is the monoclonal antibody CD99
(MIC-2), which recognizes the cell surface protein. ESFT
specimens demonstrate a crisp and strong membranous
positivity with CD99 antibody in more than 90% to
95% of cases reported. Therapeutic response assessment
is based upon tumor size changes as determined with
anatomic imaging tests. Utilization of FDG PET-CT in
staging, restaging and assessment of response to ESFT
therapy is increasing worldwide although not considered
a standard in the diagnostic workup [15]. Even children
and young adults successfully treated for their localized
ESFT, are at high risk of relapse, and must be monitored
for years by periodical medical imaging examinations,
often resulting in additional X-ray exposure. Absence of
asymptomatic ESFT diagnostic biomarkers has lent to the
reliance on clinical symptomatology and/or findings with
complementary conventional imaging modalities including
FDG PET-CT, to detect and monitor these patients.
However, imaging in and of itself is a poor means for early
cancer detection and monitoring of recurrence. Therefore,
the discovery of new ESFT biomarkers and development
of clinically useful tests for early detection and monitoring
disease progression are considerably in need.
There has been a momentum towards the direction
of personalized medicine, especially in solid pediatric
tumors such as ESFT and other pediatric sarcomas [16]. It
naturally follows that the identification of novel and robust
biomarkers as well as the tools to effectively measure
them are in dire need. Many of the biomarkers studied
regarding ESFT have been prognostic in nature and rely
upon biopsy/resection of tumor tissue [17, 18]. Currently,
there are no readily available clinical liquid-based assays

Ewing Sarcoma Family of Tumors (ESFT) encompass
a group of highly aggressive pediatric osseous and soft
tissue malignancies thought to originate from primordial
bone marrow-derived mesenchymal stem cells and
consists of small round blue cells with minimal stroma and
differentiation [1]. Ewing sarcoma of the bone, extraosseous
Ewing sarcoma, and peripheral primitive neuroectodermal
tumors (pPNET) are all considered manifestations of a
single neoplastic entity. With a peak incidence within the
second decade of life, slight male preponderance, high
incidence in those of European ancestry and approximately
3 cases/million/year [2], this malignancy continues to
remain the second most prevalent pediatric bone tumor after
osteosarcoma. ESFT can occur in any bone; however, most
typical sites of involvement are the pelvis (25%), femur
(16%), ribs (13%), spine (8%), and scapula (5%) [3]. Overt
metastatic disease is prognostic, with approximately 25%
of newly diagnosed ESFT being affected [4]. Of the ESFT
metastatic patients, 37% (or 9% of all ESFT patients) have
metastases confined to the lung or pleura [5].
Overt metastatic disease is prognostic; however, it
is evident that the preponderance of ESFT patients (even
with localized disease) harbor micrometastatic disease.
Hence, the necessity for a multidisciplinary approach
in the management of these patients, involving interval
compression chemotherapy with that of local control
(surgical and/or radiation) as well. Localized ESFT patient
outcomes based on the most recent Children’s Oncology
Group completed trial (AEWS0031) is 73% Event Free
Survival (EFS) at 5 years [6]. Outcomes continue to remain
dismal for pediatric metastatic ESFT, with a 20–30%
2- to 3-year EFS. Despite the intensification of therapies
(interval-compressed VDC/IE) and improved local
control in pediatric ESFT, 30–40% of patients experience
recurrence [7]. Most recurrences occur within 2 years
from time of diagnosis, with an EFS of less than 10% at
3 years for early recurrence (< 2 years from diagnosis) [8]
and for late recurrences (> 2 years from diagnosis) greater
than 25% OS (overall survival). The median relapsefree interval (time of diagnosis to first recurrence) is 17
months (range 5–90 months) [5]. Outside of the presence
of overt metastatic disease, no clinically relevant predictive
biomarkers exist which are indicative of the increased risk
of recurrence in localized ESFT patients. Various other
clinical prognostic factors such as age (> 15 years of age
with worse outcomes), tumor location (pelvic tumors with
worse outcomes) [6], tumor size (larger tumors > 100
mL with worse outcomes) [9] and histologic response to
induction therapy (poor response with worse outcomes)
[10]; however, have not been incorporated within pediatric
ESFT treatment risk stratification [11]. Standard circulating
tumor markers are not applicable to ESFT. Serum lactate
dehydrogenase (LDH) has been most consistently associated
with aggressive disease, but lacks ESFT specificity [12].
www.oncotarget.com
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RESULTS

FLI1 type I (TC-71), EWS-FLI1 type II (RD-ES and SKES-1), EWS-FLI1 type III (CHLA-258) fusions, as well
as COG-E-352 which carries the EWS-ERG fusion were
used as sources for sEVs. In addition to these ESFT cell
lines, Hs919. T, a benign osteoid osteoma cell line known
to lack EWS-ETS fusions was included as a negative
control (Supplementary Table 1) [37]. sEVs from each
of the ESFT and control cell lines were isolated using
ultracentrifugation [38] and the contents of the resulting
120,000 × g pellet were then characterized for markers and
size distribution (Figure 1 and Supplementary Figure 1).
Nanoparticle Tracking Analysis (NTA) indicated that
all five ESFT cell lines released a homogenous mixture
of nano-sized vesicles with varying diameters between
150–239 nm (Supplementary Figure 1), consistent with
previous reports for sEVs [39]. In addition, western blot
analysis confirmed an enrichment of exosomal markers,
Alix and CD81, in sEVs as compared to the parental cellsderived lysates (Figure 1A), further supporting the purity
of the isolated sEVs. Using a monoclonal antibody raised
against the C-terminal domain of FLI1, the expression of
the EWS-FLI1 fusion protein was also only detectable
in sEVs derived from cell lines carrying the EWS-FLI1
fusion transcripts (Figure 1A), while COG-E-352 (EWSERG) and Hs919. T cell line derived sEVs were negative.
Of note, size differences in EWS-ETS oncoproteins were
noticeable between cellular extracts and their corresponding
sEV lysates, suggesting these fusion proteins and other
sEV proteins may be post-translationally modified prior to
sorting into sEVs as previously been described [40]. Next
RT-PCR analysis demonstrated and validated that ESFT cell
lines known to have an EWS-ETS fusion were positive for
either the EWS-FLI1 or EWS-ERG transcripts (Figure 1B).
Most importantly, enrichment of the EWS-ETS transcripts
were detectable within each of the ESFT cell line derived
sEVs while absent within Hs919. T cells-derived sEVs
(Figure 1C). In addition to PCR we evaluated the mRNA
content of both cell lysates and their corresponding sEVs
using a portion of the Nanostring Elements sarcoma panel
as previously published [41]. While we were able to detect
and differentiate EWS-ETS fusion transcripts in cellular
mRNA, we were unable to detect the presence of the
fusion transcript within sEV samples using the nCounter
platform (Nanostring) and a custom designed EWS-ETS
fusion transcript panel (data not shown), which led us to
choose qPCR as our primary assay for transcript detection.
Taken together these data demonstrate that sEVs released
from ESFT cell lines harbor the pathognomonic EWS-ETS
fusion protein and transcript characteristic of ESFT.

Ewing sarcoma family of tumor cell lines
constitutively release EWS-ETS transcript and
oncoprotein in association with sEVs

Proteomic analysis of ESFT cell lined derived
sEVs identify a core set of ESFT-associated exoproteins

For this study, ESFT cell lines representative of
the most common EWS-ETS fusion types; namely EWS-

Two biological replicates of ESFT sEV preparations
were isolated from TC-71 and CHLA-258, while one was

utilizing biological fluids such as blood, serum, or urine
specifically for diagnosing ESFT, evaluating minimal
residual disease, or monitoring of disease progression [4].
To address some of these diagnostic hurdles, we turned
our attention to a class of circulating extracellular vesicles
(EVs), of which small EVs (sEVs) or exosomes have gained
considerable traction in the field of liquid-based biomarkers.
sEVs/exosomes are proving to be an abundant source
of protein- and nucleic acid-related biomarkers [19–22].
Exosomes originate through the formation of multivesicular
bodies (MVB) within the endosomal compartment of
cells [23] and are secreted into the extracellular space as a
result of fusion with the cellular plasma membrane. sEVs
contain a varying assortment of proteins, lipids, and nucleic
acids reflective of their cell of origin. The population of
sEVs within the blood is heterogenous because circulating
extracellular vesicles are released by most if not all types
of cells in the body. It is estimated that exosomes released
by platelets, lymphocytes, dendritic cells, and other immune
cells comprise 80–90% of serum/plasma exosomes [24].
In contrast to other classes of extracellular vesicles, tumor
derived sEVs/exosomes, have been found to be elevated
within the circulation of cancer patients and reflective
of their tumor burden [25, 26]. The cell specific cargo of
sEVs, including a wide array of proteins and RNAs (e.g.,
mRNA, miRNA, and LncRNA), has been shown to have
biomarker potential in several malignancies including;
gastrointestinal stromal tumor [25], pancreatic cancer [27],
acute myeloid leukemia [28] and glioblastoma multiforme
[29]. In addition, our group and others, have shown that
tumor derived sEVs play pivotal roles in intercellular
communication, tumor development, angiogenesis [30],
preparation of pre-metastatic niches [31], modulating antitumor immune responses [32] and drug resistance [33].
Tumor derived sEVs are found abundantly circulating in
blood plasma and within malignant effusions derived from
cancer patients [34, 35]. Furthermore, previous work has
suggested that tumor derived sEVs may provide a biomarker
source for ESFT [36]. The essential role of EWS-ETS fusion
transcripts makes it less likely to be down-regulated or nonexistent during tumor progression, convincingly supporting
their routine utility for diagnostic assessment in ESFT tumor
biopsied tissues but also in circulating tumor derived sEVs.
In this study we report for the first time the proteome of
ESFT-derived sEVs/exosomes and develop a clinically
useful test based on immuno-enrichment of ESFT-sEVs and
detection of the EWS-ETS fusion transcripts.

www.oncotarget.com
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isolated from RD-ES, SK-ES-1, and COG-E-352 cell
lines derived conditioned media. Each biological replicate
was analyzed as technical replicates to further establish a
reliable sEV proteome (i.e., exo-proteome) profile.
Our initial analysis of ESFT cell line derived
sEV proteomic data utilizing the Proteome Discoverer
v1.3.0.330 (Supplementary Table 2) we determined the
qualitative presence and distribution of identified proteins
(total 1,082 proteins) between the five pediatric ESFT
cell line derived sEVs, revealing a common subset of
619 sEV proteins out of 822 (TC-71), 870 (SK-ES-1),
876 (COG-E-352), 914 (CHLA-258), and 1,009 (RD-ES)
unique peptides, representing an 75%, 71%, 71%, 68%,
and 61% overlap, respectively (Figure 2). This observation
was further strengthened, i.e., of the total proteins (1,082)
identified between the five cell lines, only 5 proteins
(0.5%) were enriched solely in TC-71, 7 (0.6%) in SKES-1, 9 (0.8%) in COG-E-352, 28 (2.6%) in CHLA-258,
and 54 (5%) in RD-ES sEVs (Figure 2).
Analysis of the mass spectrometry proteomic data
from sEVs derived from ESFT cell lines, EWS-FLI1
Type I (TC-71, n = 2), EWS-FLI1 Type II (SK-ES-1,
n = 1 and RD-ES, n = 1), EWS-FLI1 Type III (CHLA258, n = 2) and EWS-ERG (COG-E-352, n = 1) were

analyzed utilizing the total averaged spectrum counts
(Supplementary Table 3) for differential protein expression
comparison analysis. For EWS-FLI1 Type I versus Type II
a differential expression in 437 proteins was noted, while
322 proteins in EWS-FLI1 Type I vs Type III, 241 proteins
in EWS-FLI1 Type II vs Type III, and 572 for EWS-FLI1
vs EWS-ERG. (Supplementary Table 4 and Figure 3).

Pathway analysis of proteomic data
Mass spectrometry proteomic data via the
Proteome Discoverer v1.3.0.330 was utilized to gain
an understanding of the origin of the core ESFT sEV
proteome using the Functional Enrichment analysis tool
(FunRich). Unsurprisingly, the largest cellular component
of origin was listed as ‘extracellular exosomal’ (~80%)
(Supplementary Figure 2A). Many of the shared ESFT
sEV proteins were found to be ubiquitously exosomal
proteins, such as membrane transport and fusion proteins
(Annexins A1, A11, A2, A5, A6, A7), tetraspanin protein
CD81, chaperone proteins (heat shock family protein
70, HSP70 and heat shock protein family 90, HSP90),
metabolic enzymes (pyruvate kinase, ATPase, G6Pisomerase, glyceraldehyde 3-phosphate dehydrogenase,

Figure 1: EWS-ETS transcript and protein are detected in ESFT cell lines and their corresponding sEVs. (A) Western

blot analysis of EWS-FLI1 protein and common exosomal markers (ALIX, CD81) in ESFT cell lines (C) and sEVs (E) from TC-71,
RD-ES, SK-ES-1, CHLA-258, and COG-E-352 and Hs919.T, a benign osteoid osteoma cell line, was used as a negative control. EWSFLI1 is detected using an antibody directed at the C-terminal region of FLI1. ALIX and CD81 common markers of exosomal and small
EV populations. (B) Expression of the EWS-FLI1 or EWS-ERG fusion transcripts in ESFT and Hs919.T (negative control) cell lines.
Expression values were normalized to the housekeeping gene GAPDH. (C) Expression levels of EWS-FLI1 or EWS-ERG fusion transcripts
in ESFT cell line derived sEVs normalized to total RNA input.
www.oncotarget.com
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enolase, aldolase, phosphoglycerate kinase 1), antigen
presenting proteins (MHC-1, H2A and complement), and
cytoskeletal structural proteins (ARP2, ARP3, cofilin
1, moesin, actin gamma 1, syndecan binding protein)
(Supplementary Figure 2).
To gain a further understanding of the functional
classification of ESFT sEV proteins, we used Protein
ANalysis THrough Evolutionary Relationships [42] 10.0
Gene ontology Molecular Function software. This software
allowed the identification of top molecular functions,
biological processes, and protein classes within our ESFT
sEV proteome. We identified 288 different molecular
functions with the uppermost consisting of protein
binding, catalytic activity, and structural molecule activity
(Supplementary Figure 2B). Out of 550 identified cellular
processes, proteins involved within the metabolome,
cellular component organization and biogenesis, biological
regulation, localization processes, and response to stimulus
were most enriched in ESFT derived sEVs (Supplementary
Figure 2C). The bulk of protein class consisted of nucleic
acid binding, hydrolase, enzyme modulator, cytoskeletal
protein, and chaperone proteins (Supplementary
Figure 2D). This analysis demonstrates that ESFT derived
sEVs carry a wide variety of proteomic content composed
of both common sEVs elements and others which may be
more specifically characteristic of ESFT.

To identify disrupted biological pathways between
EWS-FLI1 versus EWS-ERG cell line derived sEVs, a
gene set enrichment analysis (GSEA) was implemented.
This analysis demonstrated two statistically significant
pathways enriched between the comparison groups, the
ECM-receptor interaction (p-value: 0.012) and the focal
adhesion pathway (p-value: 0.026) (Supplementary
Table 5).

Identification of candidate ESFT sEVs proteins
as potential biomarkers
Subsequent to this proteomic analysis, we then
asked whether any of these ESFT sEV-proteins could
serve as potential ESFT biomarkers and be exploited
to specifically enrich for circulating tumor-derived
sEVs. The human plasma constitutes of approximately
7% proteins and considered the most complex humanderived proteome containing other tissue proteomes
as subsets [43]. To reach the full potential of ESFT
derived sEVs as a source of biomarkers and distinguish
their proteome from contaminating plasma proteins, it
is essential to differentiate specific ESFT derived sEV
proteins applying a large robust normal/healthy proteome
dataset. The Plasma Proteome Project (http://www.
plasmaproteomedatabase.org/) is the characterization of

Figure 2: Common and unique proteins to ESFT cell line derived sEVs. Venn diagram depicting quantitative measurements
from spectrometry analysis of 5 Ewing Sarcoma Family of Tumors (ESFT) cell line (EWS-FLI1 fusion Type I, II, III, and EWS-ERG
fusion) derived sEVs.
www.oncotarget.com
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the human plasma proteome by an international consortium
and is one of the largest resources of proteomics reported.
All proteins previously reported to be found within the
plasma and serum of healthy individuals were eliminated
by manually comparing our initial proteomic ESFT
cell line derived sEV dataset (Proteome Discoverer
v1.3.0.330 based data set) to that of the proteins in the
Plasma Proteome Database. This approach identified a
total of 60 potential ESFT biomarker candidates. Even
though present in ESFT-derived sEVs, CD99/MIC2 and
HINT1 were overlooked based on this type of analysis.
However, given their documented importance related to
ESFT (discussed below) we reincorporated them onto the
candidate list resulting in a total of 62 protein biomarkers
(Supplementary Table 6).
We then utilized the Ingenuity Pathway Analysis
(IPA) software platform for gene ontology and
pathway analysis to elucidate biomarkers previously
published within sarcomas (QIAGEN Inc., https://www.
qiagenbioinformatics.com/products/ingenuitypathwayanalysis). IPA is a curated database that utilizes current
knowledge available on genes, proteins, normal cellular
and pathological processes, signaling and metabolic
pathways, required for pathway construction. We utilized
the Ingenuity Biomarker Analyzer tool, to identify cellular
biological function and canonical pathways in known
proteins previously identified as biomarkers. Present

within this data set were immuno-histochemical markers
commonly expressed in ESFT, e.g., CD99/MIC2 and
CAV1 and are used clinically to differentiate ESFTs from
other small round cell tumors. Another marker identified
was Histidine triad nucleotide binding protein 1 (HINT1).
HINT1 has been shown to repress β-catenin-mediated
transcription of Wnt target genes and had been noted to be
differentially expressed between localized and metastatic
ESFT [44]. All together a total of 10 proteins previously
identified to be associated with sarcomas were further
investigated (Supplementary Table 7 and Figure 4A).
Our next step was to then confirm the presence and
enrichment of these proteins within our cell lines and cell
line-derived sEVs by western blot analysis (Figure 4B
and 4C). This analysis corroborated that CD99 and NGFR
were expressed within ESFT cell lines and enriched within
ESFT-derived sEV. The protein levels were significantly
lower or absent in the control Hs919. T cells and its
associated sEVs (Figure 4B). Likewise, HINT1, EZR,
and ENO were enriched in a majority of ESFT sEV
samples and minimally enriched or absent in control
(Figure 4B and 4C). ITGA5 (Integrin Subunit Alpha 5),
JAK1 (Janus Kinase 1), NPM1 (Nucleophosmin), and
CTNNB1 (Catenin Beta 1) were either not detected in
ESFT or not substantially enriched in ESFT samples as
compared to the control (Figure 4C). Taken together, this
analysis lead towards the identification of 5 proteins, (2

Figure 3: Differentially expressed proteins in ESFT cell line derived sEVs. Volcano plots visualizing the results of the protein

expression analysis based on the four comparisons of interest: (A) Type I versus Type II fusions, (B) Type I versus Type III fusions, (C)
Type II versus Type III fusions, and (D) EWS-FLI1 versus EWS-ERG. Horizonal black bars represent a p-value of 0.05 [e.g., –log10(0.05)].
The color of the plotted protein represents the difference in mean expression. The scale is –6 to 0 to 6 with the color scale as blue to black
to red, respectively.
www.oncotarget.com
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for sEV RNA isolation and subsequent evaluation of EWSETS fusion transcripts. Next, we utilized healthy control
plasma samples spiked with ESFT cell line derived sEVs
(Figure 5B). 1 mL of plasma from healthy control samples
was spiked with an excess of TC-71 derived sEVs (1 ×
1010). From this we immunocaptured (IP) EVs from 250 µL
aliquots using CD99 or NGFR antibodies alone or in 50/50
combination (combo) and with IgG as a negative control
(NC) (Figure 5B). We observed little to no difference in
quantification of EVs enriched from plasma with either
the single antibodies or combination (combo) (Figure 5C).
However, under these conditions we observed substantial
non-specific binding of sEVs to the beads with IgG alone
despite multiple attempts at different blocking techniques.
Even given this hurdle, we obtained 1–3 µg of total RNA
from sEVs isolated using either individual antibody or
combo (Figure 5D). Real-time qPCR revealed that IPs with
CD99, NGFR, and combo captured EVs harboring the EWSETS fusion transcript (Figure 5E). Given these data, and to
ensure that we were optimizing our ESFT sEV enrichment,
we opted to utilize the combo IP technique for subsequent
studies. To note: EVs will be used in reference towards all
particles isolated via IP method due to the IP technique itself
is incapable of enriching only sEV populations.

membrane bound and 3 cytosolic) with the potential as
ESFT sEV biomarker capability. We next evaluated the
two most promising membrane-associated biomarkers
(NGFR and CD99/MIC2) by IHC on primary tumor
biopsies. Over 90% of tumor biopsies expressed high
levels for membranous CD99. For NGFR, over 50% of
tumors stained between medium and high levels and less
than 18% were negative for the marker (Supplementary
Figure 3).

Immunoprecipitation with NGFR and CD99
enriches for tumor derived sEVs
To begin to develop a clinical assay based on
circulating tumor derived sEVs, we opted to exploit the
membranous location of CD99 and NGFR to develop a tool
capable of enriching ESFT-associated sEVs from plasma
in pediatric patients. Our group as well as others have
attempted to detect exosomal EWS-ETS transcripts directly
from plasma, but have been relatively unsuccessful. To
begin, we determined the minimal plasma volume required
for sEV detection in order to best minimize the risks of
hemodynamic instability or iatrogenic anemia within our
pediatric patient population. We isolated sEVs from 250
µL and 500 µL of plasma from 3 healthy individuals using
ultracentrifugation (120,000 × g pellet) and then isolated
total RNA from the resulting pellet. The amount of total
RNA was compared to RNA isolated from a control volume
(5 µg) of ESFT cell-derived sEVs (Figure 5A). From this
we determined that 250 µl would be a sufficient volume

Identification of EWS-ETS transcripts from
clinical samples
To transition our assay into a pre-clinical
application, we isolated EVs using immuno-enrichment

Figure 4: Identification of potential sEV-associated ESFT biomarkers. (A) Cellular localization of potential ESFT sEV
biomarkers (Intraluminal, rectangles; plasma membrane, ovals). (B–C) Validation of ITGA5 (Integrin Subunit Alpha 5), JAK1 (Janus
Kinase 1), CTNNB1 (Catenin Beta 1), EZR (Ezrin), ENO (Enolase), and NPMN1 (Nucleophosmin 1) as potential sEV-protein biomarkers
for ESFT by western blot analysis.
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from 10 clinical pediatric ESFT plasma samples (ages 1
to 17 years of age) and 6 plasma samples from healthy
control individuals (< 20 years of age) (Table 1). From
250 µL of healthy patient plasma we immunoprecipitated
an average of 2 × 108 EVs. In comparison, we isolated
~16-fold more EVs (average 32 × 108 EVs, P = 0.01)
utilizing the equivalent volume of ESFT pediatric patient
plasma (Figure 6A). This was true for both subsets
of ESFT patients, localized (P = 0.01) and metastatic
(P = 0.04) disease. However, there was no significant
variance between the number of EVs in ESFT patients
with localized vs. metastatic disease. ROC/AUC analysis
of these data resulted in a 95% confidence interval with
an AUC of 0.9242 (Figure 6B). Using qRT-PCR analysis
of the nucleic acid content of the isolated EVs by IP, we
identified the EWS-ETS fusion transcript in 70% (7 of
10) of pediatric clinical samples (60% ESFT metastatic
and 83% ESFT localized identified) (Figure 6C), with
no false positives. cDNA from EVs derived from TC71 and Hs919. T cell lines were used for positive and
negative controls, respectively. These results equated to
a positive predictive value (PPV) of 1.00 (0.63, 1.00)
and negative predictive value (NPV) of 0.67 (0.30, 0.93)
for detecting the EWS-ETS fusion transcript. To evaluate
if this methodology is more efficacious than evaluating
EVs as a whole, we prepared matched samples from 4
ESFT pediatric patients using immuno-isolation with
combo (CD99+NGFR) or a member of the tetraspanin
superfamily CD9 (a common sEV marker) in 250 µL of
plasma. While no significant differences in the number of

EVs were isolated (Supplementary Figure 4A), we were
able to identify the EWS-ETS transcript in all of the ESFT
patients using the COMBO immuno-isolation approach,
but only 50% of the patients using CD9 antibody alone
(Supplementary Figure 4B). These pre-clinical data are
strongly supportive of the approach to use CD99 and
NGFR for the enrichment for ESFT specific EVs from
clinical patient plasma and that the proposed liquidbase biopsy can serve as a clinical tool for the diagnosis,
monitoring of disease, and early detection of relapse
(Figure 6D).

DISCUSSION
As with the majority of pediatric malignancies,
translational research in ESFT lags behind work being
done in adult oncology. In this study, we have sought
to advance the scientific literature of ESFT by defining
for the first time the proteome of ESFT-associated sEVs.
The idea of a “liquid biopsy” has prompted a plethora
of studies on sEV biomarkers in cancer [45]. However,
isolation of tumor-associated sEVs directly from patient
blood samples is particularly challenging, in part, due to
lack of specific markers capable of distinguishing cancer
from non-cancerous derived sEVs. We hypothesized
that the we could utilize protein biomarkers towards the
enrichment of ESFT-associated sEVs, given the EWSETS fusion transcript is not readily detected in plasma.
Additionally, we speculated that, in doing this, we
could significantly increase the sensitivity in detection

Figure 5: Development of an IP to enrich for ESFT-specific sEVs. (A) Amount of total RNA (in nanograms) recovered from

sEVs isolated through ultracentrifugation from human plasma samples (250 µL or 500 µL) and from TC-71 derived sEVs as a control.
(B) Schematic depicting the methodology of our IP strategy. (C–E) Particles recovered (C), total RNA (in ng) recovered (D), and the
relative abundance of EWS-ETS transcripts (E) obtained from sEVs isolated from sEV-spiked plasma samples. EWS-ETS expression
comparison utilizing CD99 versus NGFR versus CD99 + NGFR (COMBO) antibody cocktail for enrichment of ESFT sEVs. The COMBO
demonstrated greater yield for increased enrichment of ESFT sEVs.
www.oncotarget.com
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Table 1: Patient information
ID#
1
8
9
13
14
16
18
20
23
25
026785
236786
026839
026940
027153
027161

Age (Years)
16
6
9
1.6
6
12
15
6
16
17
3
20
2
11
20
18

Gender
M
F
F
F
M
F
F
F
F
M
M
M
F
F
M
M

EWSR FISH
+
+
+
+
+
+
+
+
+
+
NA
NA
NA
NA
NA
NA

Localized/Metastatic
Metastatic
Localized
Metastatic
Localized
Metastatic
Localized
Localized
Metastatic
Metastatic
Localized
NA
NA
NA
NA
NA
NA

Ten (10) pediatric ESFT patients and 6 non-oncology pediatric patients were utilized for the analysis Ewing Sarcoma derived
small extracellular vesicles (sEV).
of otherwise low frequency mutations, i.e., EWS-ETS,
which is diagnostic of the disease. By initiating studies to
develop a liquid-based biopsy we sought to improve the
molecular tools for the diagnosis, detection, and disease
monitoring of patients with ESFT.
The use of blood-based diagnostics, referred to as
liquid biopsies, provides an opportunity improve diagnosis
and to monitor disease states in real-time [46]. Circulating
tumor cells (CTCs) and circulating tumor DNA (ctDNA)
have been used clinically, but their diagnostic value is
still limited for many cancer types based on sensitivity
and specificity of the respective assays. For example, the
heterogeneity and rarity of CTCs define the challenges
of purifying an extremely small number of CTCs from
a large number amount of other cells in a large blood
volume (typically 7.5 mL) [47]. In metastatic cancer
setting, CTCs within the peripheral circulation occur at
an estimated number of one CTC per 1 × 105–7 peripheral
blood mononuclear cells [48]. Relevant to our studies,
Benini et al. reported that CD99+ CTCs were detected
in 4 of 23 peripheral ESFT using 10-mL blood samples
from patients age range of 13–32 years. ctDNA is another
option being promoted as an alternative noninvasive
method that overcome many difficulties related to tissue
biopsy (e.g., spectrum of mutations limited to a single
region of the tumor, serial sampling usually not feasible,
etc.). Though significant progress has been accomplished
in the field of ctDNA diagnostics, especially those based
on next generation sequencing, serious limitation exists,
given the vast majority of circulating DNA is primarily
composed of normal cell free DNA (cfDNA) [49, 50].
www.oncotarget.com

Relevant to our studies, Shulman et al. utilizing an NGS
hybrid capture assay and an ultra-low-pass whole-genome
sequencing assay to detect ctDNA in a median of 2 mL
of banked localized ESFT pediatric patient plasma from
Children’s Oncology Group (COG), demonstrated ctDNA
in 53.3% (41/77) of newly diagnosed patients [51].
Allegretti et al. demonstrated that EWS-FLI1 Type I and
Type II rearrangements could be identified, regardless of
patient-specific EWS-FLI1 DNA breakpoints in circulating
tumor RNAs (ctRNAs) in 4 patients (1 metastatic and 3
localized) ranging in ages from 8–45 years utilizing 1.8
mLs of plasma. Although the most frequent translocation
partner of EWS is FLI1, with the common fusion joining
EWS exon 7 in frame with FLI1 exon 6 (type 1 fusion),
there are several other EWS-FLI1 type fusions, as well
5–10% of patients with ESFT have an EWS partner ERG.
Our method focused on ESFT exo-proteins to immunoenrich tumor-associated circulating EVs for the subsequent
detection of EWS-FLI1 Types I, II, and III and EWS-ERG
fusion transcripts within pediatric patient plasma. ESFT is
regarded as a malignancy of childhood and adolescence
and thus rare in over the age of 40, hence our focus on
enrolling patients who consist of the majority of this
disease population in this assay. A limitation in pediatric
studies such as this is in part due to the incidence of ESFT
in children and young adults within the United States and
the volume of blood ethically and safely obtainable, hence
we have utilized 10 pediatric patients in this study and
were able to detect EWS-ETS fusion transcripts in both
metastatic and localized subset of patients utilizing only
250 µL of plasma. We have expanded and improved upon
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prior published accomplishments [52–54] by directly
identifying ESFT sEV-associated protein biomarkers
which enabled us to enrich for ESFT-specific sEVs
(AUC = 0.92) and concordantly detecting the EWS-ETS
fusion transcript (PPV = 1.00 and NPV = 0.67) from as
little as 250 µl of archival plasma samples. The approach
by Benini et al. [55], Allegretti et al. [56], and our own
circumvent the requirement to sequence patient-specific
breakpoints, obtain long tumor DNA fragments from fresh
tumor, and design patient-specific primer sets. Based on
the above technical background, our clinically relevant
assay could be applied to diagnose and potentially monitor
ESFT patients during therapy and then off therapy for
recurrence of disease.
In this first proteomic analysis of ESFT derived
sEVs, we demonstrate the presence of 618 core enriched
ESFT-sEV proteins, including ESFT associated proteins
such as CD99/MIC2, caveolin, and GLG1 which have
recently been proposed as markers for ESFT [57]. Among
the top sEV biomarker candidates, we identified both
HINT1 and NGFR (p75NTR). Previously, HINT1 was
found to repress β-catenin-mediated transcription of
Wnt target genes, and had been noted to be differentially
expressed between localized and metastatic ESFT [44].
NGFR, also known as low-affinity nerve growth factor,

a member of the tumor necrosis receptor family and has
been implicated in the paracrine growth regulation of a
number of neuronal as well as non-neuronal tumor types
[58], such as prostate cancer, invasive ductal breast cancer,
pancreatic carcinoma and malignant melanoma. NGFR is
abundantly expressed during development but in adult
organisms is known to be downregulated. However, the
NGFR is re-expressed in conditions of increased neuronal
cell death [59]. In a study done by Fanburg-Smith and
Miettinen, non-neural mesenchymal tumors showed
variable NGFR expression based on tumor type, with
rhabdomyosarcoma demonstrating a 90% positivity of 94
cases, Ewing Sarcoma 32% in 31 cases and extraskeletal
osteosarcomas 23% in 13 cases [60]. Likewise, we
observed over 80% of tissue samples positive for NGFR
by IHC. Both CD99 and NGFR on subsequent analyses of
the mass spectrometry sEV proteomics utilizing Proteome
Discoverer v2.3.0.523 confirmed that both of these
proteins are in the top 15% based on the respective MS1
data and PSM. In addition to ESFT-specific proteins, the
detection of chimeric mRNAs transcribed from the EWSETS fusion genes are a valuable tool in the molecular
diagnosis of ESFTs [61]. Overall the ESFT genome is
genetically quiet with few genomic aberrations/mutations
identified compared with most cancers [62–64]. In recent

Figure 6: Enrichment of ESFT-sEVs from clinical ESFT plasma samples. (A) Total concentration of sEV’s isolated from 250

µL of pediatric ESFT (n = 10) and healthy plasma (n = 6). (B) Area Under the Curve (AUC) analysis (A) of total sEV counts in cases and
controls following immuno-enrichment. (C) Detection of the EWS-ETS transcript by qRT-PCR, * denotes samples that crossed threshold and
are considered positive, total of 7/10. cDNA from sEVs derived from TC-71 and Hs919.T cell lines served as positive and negative controls,
respectively. (D) Localized and metastatic pediatric ESFT patient isolated sEVs demonstrating size threshold between 120–154 nm.
www.oncotarget.com

3004

Oncotarget

years, it has become abundantly clear that the EWSETS rearrangements are the most important molecular
determinant of tumorigenesis and progression of the
ESFT [65]. This makes the identification of ESFT related
proteomics and translocations in circulation particularly
appealing because they are not likely to be lost during
tumorigenesis and tumor progression. This current study
is the first to identify the EWS-ETS transcript with high
specificity in sEVs isolated from pediatric ESFT patient
plasma samples by combining sEV proteomics and
immuno-enrichment techniques.
The composition of sEVs is not sporadic in nature,
suggestive that the incorporation of proteomic and RNA
cargo into sEVs are a regulated process. Different forms
of post translational modifications of proteins have been
reported to occur in sEVs, such modifications permit for
protein versatility via influencing their activation state,
subcellular localization, stability, and protein: protein
interactions [66]. Certain aspects of post-translational
modification have been shown to be integrated within the
biopathway of sEV release. The generation and progression
of many diseases have been associated with sEVmediated transport of misfolded disease-causing proteins
as well [67]. Loading of proteins within sEVs because
of protein damaging modifications such as oxidation
[68] or misfolded proteins has also been well described
[69]. Our results suggest that some proteins within ESFT
derived-sEVs/exosomes, including EWS-ETS fusion
proteins, are likely post-translationally modified prior to
sorting. The presence of abundantly enriched proteins
on the membrane of sEVs as well as those of modified
proteins in sEVs offers an excellent opportunity to
develop highly specific techniques for the isolation and
identification of sEVs for biomarker utility; thus, offering
an unprecedented opportunity to garner information for
pediatric sarcomas in a non-invasive manner and help
potentially design curative options that would further
improve on the OS of these patients. A crucial challenge
to our assay is in achieving absolute sensitivity, while
avoiding any false positives. The latter is not a major issue
given that EWS-ETS fusion are uncommon in other cancer
types; however, the presence of the EWS-ETS transcript
is as low as < 1 copy/105 sEVs as we have previously
published [52], which is a likely reason for our inability
to achieve 100% specificity with the current assay. There
are several approaches that may further enhance aspects
of our technique. Effective combinations of antibodies
towards ESFT sEVs membrane-based antigens discovered
through our proteomics alongside NGFR and CD99 for
immunocapture, rather than dual-antibody approaches
implemented within our study, may potentially further
improve sEV isolation. Another approach would be
to increase the volume of plasma input into our assay
to 500–1,000 µL. Prior studies have demonstrated
approximately 2.11% of the total RNA content within
sEVs are mRNA fragments, while microRNAs are vastly
www.oncotarget.com

enriched within these circulating extracellular vesicles. We
are currently studying the utility of ESFT sEV miRNAs as
biomarkers in conjunction with our EWS-ETS detection
methodologies. By incorporating several markers for the
detection and diagnosis of ESFT, a biomarker signature as
such will further increase the sensitivity of this assay to
enable the identification of even minimal residual disease
presence during therapy and even post-therapy.
In order to further advance the development of sEVs
as biomarkers in ESFT, our ongoing studies are integrating
protein markers identified through our study into our
prototypic microfluidic chip. As discussed above, we
have recently demonstrated the quantitative measurement
of EWS-FLI1 mRNA copy numbers in pPNET-derived
sEVs [52]. Although a rare disease, development of this
type of integrated assay could aid in the diagnosis of all
members of the ESFT family. We are currently in process
of developing of single microfluidic platform using our
validated capture reagents to streamline the enrichment
of tumor derived sEVs and quantitative measurement of
EWS-ETS fusion transcripts in ESFT. Studies of ESFT
tumor derived sEVs may reveal possible new important
therapeutic targets, as well as perhaps yield RNAs
prognostic for tumor aggressiveness and chemotherapeutic
sensitivity allowing clinicians to better treat this pediatric
malignancy.

MATERIALS AND METHODS
Cell line and culture conditions
Hs919. T, SK-ES-1, RD-ES were purchased from
the American Type Culture Collection. In addition,
TC-71, COG-E-352, and CHLA-258 cell lines were
obtained from the Children’s Oncology Group (COG).
All cell line identities were confirmed by short tandem
repeat profiling via the Clinical Molecular Oncology
Laboratory at KUMC and the causative mutations in
ESFT were confirmed by FISH utilizing the EWSR1
break apart probes for EWS translocation at Children’s
Mercy Clinical Genetics and Genomics Laboratories. All
cell lines were cultured at 37°C under a 5% humidified
CO2 atmosphere. TC-71, COG-E-352 and CHLA-258 cell
lines were maintained in Iscoves Modified Dulbecco’s
Medium (IMDM), supplemented with L-glutamine (3
mM), insulin, and transferrin (5 mg/ml each), selenium
(5 ng/ml), and 20% heat-inactivated exosome free FBS
(whole medium). RD-ES cell line was maintained in
RPMI 1640 with L-glutamine, supplemented with 15%
heat-inactivated exosome free FBS (whole medium). SKES-1 was maintained in McCoy’s 5A with L-glutamine
supplemented with 15% heat-inactivated exosome free
FBS (whole medium). Hs919. T cells were maintained
in DMEM with high glucose with L-glutamine,
supplemented with 20% heat-inactivated exosome free
FBS (whole medium). All cell lines were cultured in
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the presence of 10% penicillin streptomycin to prevent
bacterial growth/contamination.

acetonitrile to 40% acetonitrile in 0.1% formic acid. The
eluate was introduced into the LTQ-Velos-Orbitrap ELITE
+ ETD mass spectrometer using a Nanospray Flex source
(ThermoElectron, Waltham, MA, USA). An Orbitrap Elite
– ETD mass spectrometer (ThermoElectron) was used to
collect data from the LC eluate. An Nth Order Double
Play with ETD Decision Tree method was created in
Xcalibur v2.2. Scan event one obtained an FTMS MS1
scan (normal mass range; 60,000 resolution, full scan
type, positive polarity, profile data type) for the range
300–2000 m/z. Scan event two obtained ITMS MS2 scans
(normal mass range, rapid scan rate, centroid data type)
on up to ten peaks that had a minimum signal threshold
of 20,000 counts from scan event one. Each sample was
injected twice yielding essentially a technical replicate, to
aid with observation and ID of low abundant proteins. A
decision tree was used to determine whether CID or ETD
activation was used. An ETD scan was triggered if any
of the following held: an ion had charge state 3 and m/z
less than 650, an ion had charge state 4 and m/z less than
900, an ion had charge state 5 and m/z less than 950, or
an ion had charge state greater than 5; a CID scan was
triggered in all other cases. The lock mass option was
enabled (0% lock mass abundance) using the 371.101236
m/z polysiloxane peak as an internal calibrant. Initially
data dependent spectra search was directed by Proteome
Discoverer v1.3.0.330 (ThermoElectron) using Mascot
v2.1 and Sage-N Sorcerer Sequest algorithms and the
UniprotKB Homo sapiens reference proteome canonical
and isoform sequences (7/10/2013 version). Search
parameters included: variable methionine oxidation, fixed
cysteine carbamidomethylation, up to 2 missed tryptic
cleavages, 50 ppm precursor error for MS1 Orbitrap
FTMS data, 0.8 Da error for CID-based MS2 LTQ data
and 1.2Da error for ETD-based MS2 data. In order to
estimate the false discovery rate, a decoy database was
generated from this database with the program decoy. pl
(from http://www.matrixscience.com/).
The ESFT cell line derived sEV mass spectrometry
proteomics data was evaluated by Proteome Discoverer
v2.3.0.523 (ThermoElectron) for imputation, matchbetween-runs, normalization steps, and protein
modification for carbamylation to address effects of urea
introduced during the FASP protocol. Search parameters
included: variable methionine oxidation, fixed cysteine
carbamidomethylation, up to 2 missed tryptic cleavages,
50 ppm precursor error for MS1 Orbitrap FTMS data,
0.8 Da error for CID-based MS2 LTQ data and 1.2Da
error for ETD-based MS2 data. Technical duplicate data
were searched and integrated as one sample. In order to
estimate the false discovery rate, a decoy database was
generated from this database with the program decoy.
pl (from http://www.matrixscience.com/). For samples
with peptides not confidently identified via Proteome
Discoverer v2.3.0.523 utilized mass tolerance windows
and chromatographic alignments to determine peptide

sEV isolation from conditioned medium of
cultured cells
ESFT cell lines were grown and cultured in five
T175 cm2 flasks containing 10% exosome-free FBS
medium for 48–72 hours until cellular sub-confluency of
~70% was reached. The benign osteoid osteoma control
cell line, Hs919. T was cultured in five T175 cm2 flasks
in 20% exosome-free FBS media for 168–240 hours
until cellular sub-confluency of ~60–70%. Media were
collected and immediately centrifuged at 2,500 rpms for 5
minutes to eliminate cellular debris. A total of 150 mL of
conditioned medium was collected and ultra-centrifuged
at 4°C for 45 minutes at 8,700 rpm (10,000 × g). The
supernatant was then collected and ultracentrifuged again
at 4°C for 75 minutes at 28,800 rpms (110,000 × g). sEV
pellets were washed with PBS and were collected by
ultracentrifugation at 4°C for 60 minutes at 35,800 rpms
in Beckman Coulter Quik-Seal Centrifuge Tubes. Finally,
each sEV pellet was resuspended in 50–100 µl of PBS
based on pellet size and then stored at –80°C.

Nanoparticle tracking analysis (NTA)
Size and concentration of isolated and purified cell
line derived sEV analysis was via the NanoSight LM10
(NanoSight Ltd., Minton Park, Amesbury, UK). A 1:1500
sEV pellet dilution in PBS was used for this analysis.
NTA is a system for particle size analysis ranging from
30–1,000 nm, with lower detectable limits dependent on
the refractive index of the nanoparticles. This technique
combines laser light scattering microscopy with a chargecoupled device (CCD) camera, enabling the visualization
and recording of nanoparticles within solution.

sEV proteomics analysis
ESFT cell line derived sEV were reduced with 0.1
M DTT for 60°C for 30 min prior to dilution into FilterAided Sample Preparation (FASP) buffer (8 M urea, 0.1
M Tris-HCl pH 8.5) and transferred to a Microcon-10
(EMD Millipore, Billerica, MA, USA) 10kDa centrifugal
for trypsinization by the FASP method [70, 71]. Tryptic
digests were trap cleaned using C18 PROTO™ Ultra
MicroSpin columns (Nest Group, Inc, Southborough, MA)
then lyophilized and redissolved into 2% acetonitrile/0.1%
formic acid prior to LCMS analysis. Tryptic peptides
were separated using an EASY n-LC (Thermo) UHPLC
system and a 360 µm OD × 100 µm ID fused silica
tip packed with 10 cm of Jupiter 5 µm C18 300 Å
material (Phenomenex, Torrance, CA, USA). Following
injection of the sample onto the column, separation was
accomplished with a 75 min linear gradient from 2%
www.oncotarget.com
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presence. With presence of an m/z signal, area of the ion
was extracted and utilized to populate missing values.
For runs without m/z values within the mass accuracy
window nor chromatographic retention time then no value
was recorded. MS1 area values for peptides with high
confident MS2 data were represented as high signal levels
(green values). MS1 area values for peptide features that
match within mass accuracy tolerance and retention time
tolerance to high confidence data in a separate LCMS run
were represented as peak found but not sufficient for MS2
validation (yellow values). For non-detectable proteins
without sufficient information to assign high confidence
spectra (green value) nor with mass accuracy or retention
time tolerances (yellow data), no signal or red value was
assigned.

To identify disrupted biological pathways between
EWS-FLI1 versus EWS-ERG cell lines, a gene set
enrichment analysis (GSEA) was implemented in R using
the package gage [72]. Protein expression data (total
spectrum count) from the EWS-FLI1 (n = 6) and EWS-ERG
(n = 1) cell lines were used as the basis of comparison. The
predefined gene set used was derived from KEGG pathways
and stored in the 'kegg.gs' data set in the gage package.

SDS-PAGE and western blot analysis
sEV samples and cell lysates were prepared in
radioimmunoprecipitation assay (RIPA) buffer and separated
by adding 40 µg protein on 7%, 10%, or 4–20% MiniPROTEAN® TGX™ Precast Gels, (BioRad, Hercules, CA,
USA). The completed gels were transferred to a supported
nitrocellulose membrane (BioRad). The membranes
were blocked with 5% non-fat milk for one hour with
gentle rocking. Membranes were incubated with primary
antibodies overnight and then washed thrice for 10 minutes
before addition of HRP conjugated anti-rabbit or anti-mouse
secondary antibody (BioRad) for 1 hour. Membranes were
subsequently washed and treated with ECL Western Blotting
Substrate (Fisher Scientific) according to manufacturer’s
instructions and antibodies used were either rabbit or mouse
Isotype (Supplementary Table 8).

Bioinformatics analysis
Initial analysis of mass spectrometry proteomics
dependent spectra directed by Proteome Discoverer
v1.3.0.330 identified 1082 proteins. Protein identity and
quantitative data were exported for further statistical
and bioinformatic analysis. The list of differentially
enriched proteins in sEV were submitted to identify the
enrichment of biological processes in sEV according their
gene ontology annotation extracted from the UniProt
database. Qualitative data generated from proteomic mass
spectrometric analysis were analyzed using Ingenuity
Pathway Analysis (IPA; Ingenuity System, Redwood City,
CA, USA; http://www.ingenuity.com), Plasma Proteome
Database (http://www.plasmaproteomedatabase.org/) and
Exocarta Vesiculopedia to identify potential biomarker
sEV signatures and their application in pediatric sarcomas.
Quantitative data from proteomic mass
spectrometric analysis were analyzed using the R
statistical programming language (http://cran.r-project.
org) using R version 3.6.1. For each biological replicate,
there were two technical replicates in which total spectral
counts were available. If the total spectral count was “0”
or “NA” it was replaced with a value of “0.5”. These total
spectrum counts were averaged for each pair of technical
replicates and then log2 transformed for analysis. Protein
expression data collected from ESFT cell line derived
sEVs from EWS-FLI1 Type I fusion (TC-71, n = 2),
EWS-FLI1 Type II fusion (SK-ES-1, n = 1 and RD-ES,
n = 1), EWS-FLI1 Type III fusion (CHLA-258, n = 2),
and EWS-ERG fusion (COG-E-352, n = 1) was log2
transformed prior to analysis. Due to the lack of biological
replicates for some of the cell lines, one-way analysis of
variance (ANOVA) models were fit independently to each
of the proteins and linear contrasts were used to test the
comparisons of interest. P-values and 95% confidence
intervals were calculated for each of the linear contrasts.
Volcano plots were generated for each comparison of
interest with the difference in mean log2 (expression)
plotted versus the -log10 (p-value).
www.oncotarget.com

Immuno-pulldown and analysis of specific
population of plasma-derived sEVs
Immuno-pulldown of sEVs required two overnight
18 to 20-hour incubation steps. Day 1 consisted of
Dynabead™ washes and immobilization of antibodies.
Dynabead Wash-1,000 µg (100 µL) of Dynabeads™
M-270 Streptavidin beads were washed three times in PBS
Buffer. Immobilization of Antibodies-10 µg of biotinylated
antibody were incubated with beads overnight with 1,000
µg of Dynabeads. Day 2 consisted of Dynabead washes
and immobilization of exosomal proteins. Dynabead Washantibody coated beads were separated by use of a magnet.
Supernatants were removed and subsequently beads
were washed 4–5 times with PBS containing 0.1% BSA.
Antibody coated beads were then resuspended in 100 µL.
A total of 50 µL of the antibody coated bead suspension
was placed in 250 µL of plasma and incubated overnight
to immobilize sEV membranous proteins. Day 3 consisted
antibody coated beads exosomal conjugate washes with
PBS and then separation with Exoquick™ Exosome
Precipitation solution (System Biosciences) with magnet to
dissociate the biotin-streptavidin bond.

qRT-PCR of exoEWS-ETS fusion transcripts
RNA isolated from cells and sEV samples were
by utilizing the miRNeasy kit (Qiagen) in combination
with phase lock tubes (5-Prime) according to the
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manufacturer protocols for total RNA isolation. Prior to
RNA isolation, sEV pellets were treated with RNAse
A (Thermo Fisher) at a concentration of 5 µg/ml for 30
minutes at 4°C. cDNA was made from 50–100 ng total
RNA and using SuperScript IV VILO cDNA synthesis
kit (Thermo Fisher). cDNA from cell lines was diluted
(1/4) with TE buffer. cDNA from sEV samples was not
diluted further. For detection of the EWS-FLI1 types I,
II, and III transcript we used the forward primer EWSF
5′-GCCAAGCTCCAAGTCAATATATAGCCAACAG-3′,
and
the
reverse
primer
FLIR
5′-GGGCCGTTGCTCTGTATTCTTACTG-3′.
For
the detection of EWS-Erg fusion transcript we utilized
the EWSF forward primer with the reverse primer
ERGR1
5′-GAGTTGGAGCTGTCCGACAGG-3′.
For each transcript we used a Fam-labeled probe
5′-GCAGCAGCTACGGGCAGCAG-3′. All primers and
probes were manufactured by IDT. qRT-PCR assays were
run on a CFX96 (BioRad) in volumes of 20 µl according to
the following conditions: 50°C, 3 minutes; 95°C, 10 minutes;
then 40 cycles of 95°C, 15 seconds; and 54°C, 60 seconds.

model (ANOVA) was used to compare the number of EVs
(particles per mL) assessed in plasma samples collected
from healthy control individuals (n = 6) and clinical
pediatric ESFT patients (n = 10). Briefly, the number of
EVs was modeled as the dependent variable, against a
single independent variable representing the health status
of the individual (e.g., healthy plasma, ESFT localized,
and ESFT metastatic). Parameter estimates obtained
from the one-way ANOVA model were used to construct
specific contrasts, which included a comparison of the
mean number of EVs between: ESFT (both localized
and metastatic) versus healthy, localized ESFT versus
healthy, metastatic ESFT versus healthy, and localized
ESFT versus metastatic ESFT. The positive predictive
value (PPV) and negative predictive value (NPV) for
detecting the EWS-ETS fusion transcript were computed
using epitests function in the R package epiR. Confidence
intervals for the PPV and NPV were calculated using a
previously described procedure [70].

Pediatric sarcoma patient biobanking

ESFT: Ewing Sarcoma Family of Tumors; sEVs:
small Extracellular Vesicles; PNET: peripheral primitive
neuroectodermal tumors; MVB: multivesicular bodies;
EFS: Event Free Survival; OS: Overall survival; CTCs:
Circulating tumor cells; ctDNA: circulating tumor DNA.
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